Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

999
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
999
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

371
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
371
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.3K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.3K
Cooperative Binding of Transcription Regulators02:13

Cooperative Binding of Transcription Regulators

2.0K
2.0K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.1K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bispecific Antibodies in Hematologic Malignancies in the Outpatient and Community Settings.

Advances in hematology·2026
Same author

Evolving therapeutic pipeline for tumor-infiltrating lymphocytes in metastatic melanoma - a review.

Frontiers in immunology·2026
Same author

Consolidation enfortumab vedotin and pembrolizumab after cisplatin induction in metastatic urothelial cancer: Outcomes of complete response and bladder preservation.

The Journal of international medical research·2026
Same author

Efficacy and safety of approved cellular therapies and bispecific antibodies in solid tumors: the current state.

Discover oncology·2026
Same author

New Validated Staging System for Light Chain (AL) Amyloidosis With Stage IIIC Defining Ultra-Poor Risk: AL International Staging System.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Optimizing Natural Killer Cellular Therapy in Acute Myeloid Leukemia.

American journal of clinical oncology·2025

Related Experiment Video

Updated: Aug 8, 2025

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis
06:28

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Published on: November 10, 2023

2.2K

Therapy-related core binding factor acute myeloid leukemia.

Binsah George1, Binoy Yohannan1, Virginia Mohlere1

  • 1Department of Hematology/Oncology, McGovern Medical School, The University of Texas Health Sciences Center at Houston, 6410 Fannin, Suite 830 Houston, TX 77030, USA.

International Journal of Hematologic Oncology
|March 6, 2023
PubMed
Summary

Therapy-related core binding factor AML (t-CBF-AML) arises from prior cancer treatments. While having better outcomes than other therapy-related AML, t-CBF-AML still shows poorer survival than de novo CBF-AML.

Keywords:
therapy-related acute myeloid leukemiatherapy-related core binding factor acute myeloid leukemia

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

200
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.5K

Related Experiment Videos

Last Updated: Aug 8, 2025

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis
06:28

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Published on: November 10, 2023

2.2K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

200
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.5K

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Therapy-related acute myeloid leukemia (t-AML) develops following chemotherapy or radiation.
  • Core binding factor AML (CBF-AML) subtypes, characterized by specific fusion genes (RUNX1::RUNX1T1 or CBFB::MYH11), can arise as t-AML.
  • Therapy-related CBF-AML (t-CBF-AML) represents 5-15% of CBF-AML cases and presents unique clinical considerations.

Purpose of the Study:

  • To review the pathogenesis of t-CBF-AML.
  • To discuss common mutations associated with t-CBF-AML.
  • To explore current and emerging therapeutic options for t-CBF-AML.

Main Methods:

  • Literature review of studies on t-AML and CBF-AML.
  • Analysis of data on cytogenetics, molecular alterations, and treatment outcomes.
  • Synthesis of information on pathogenesis and therapeutic strategies.

Main Results:

  • t-CBF-AML, despite favorable cytogenetics, exhibits worse overall survival compared to de novo CBF-AML.
  • While sensitive to standard CBF-AML therapies like high-dose cytarabine, t-CBF-AML outcomes remain suboptimal.
  • Understanding the specific mutational landscape and pathogenesis is crucial for improving t-CBF-AML treatment.

Conclusions:

  • t-CBF-AML presents a distinct clinical entity within therapy-related myeloid neoplasms.
  • Further research into targeted therapies and understanding disease-specific mutations is needed.
  • Improving survival for t-CBF-AML patients requires tailored treatment approaches.